Riskpilot← Back to searchSign inGet full accessInpare ApS
APSDissolvedCVR 37138789Agern Alle 24Manufacture of pharmaceutical preparations · NACE 2120Est. 2015— employees
Revenue 2023
DKK -219K
+85% vs 2022
EBITDA margin
119.7%
-121% vs 2022
Equity ratio
-905.2%
Financial strength
Net profit 2023
DKK -273K
-91% vs 2022
| Revenue | DKK -219K | +85% |
| EBITDA | DKK -262K | -121% |
| Net profit | DKK -273K | -91% |
| Total assets | DKK 81K | +1040% |
| Equity | DKK -736K | -59% |
| Employees | — | — |
Legal name
Inpare ApS
CVR number
37138789
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
24. september 2015
Share capital
DKK 75.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af den administrerende direktør.
Address
Agern Alle 24
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | -27 | -100 | -197 | -98 | -118 | -219 |
| Staff expenses | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -127 | -168 | -27 | -100 | -197 | -98 | -118 | -262 |
| Depreciation & amort. | -5 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -133 | -168 | -27 | -100 | -197 | -98 | -118 | -262 |
| Net financials | 0 | -3 | 0 | 0 | 0 | -0 | -0 | -20 |
| Profit before tax | -133 | -170 | -27 | -100 | -197 | -98 | -119 | -282 |
| Tax | -29 | -37 | -1 | -22 | -64 | -22 | 24 | -9 |
| Net profit | -103 | -133 | -26 | -78 | -133 | -77 | -143 | -273 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 52 | 60 | 44 | 36 | 119 | 89 | 7 | 81 |
| Equity | 52 | -6 | -33 | -110 | -243 | -320 | -463 | -736 |
| Long-term debt | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 | 66 | 77 | 147 | 362 | 409 | 470 | 817 |
| Total debt | 1 | 66 | 77 | 147 | 362 | 409 | 470 | 817 |
EBITDA margin
-26188200.0%
This company
15.8%
Market median
-165748201% vs market
20162023
Equity ratio
-905.2%
This company
38.2%
Market median
-2470% vs market
20162023
Return on equity
-27284700.0%
This company
18.4%
Market median
-148286513% vs market
20162023
Net profit margin
-27284700.0%
This company
8.1%
Market median
-336848248% vs market
20162023
Asset turnover
-2.69×
This company
1.12×
Market median
-340% vs market
20162023
Debt / equity
1.11×
This company
0.62×
Market median
-79% vs market
20162023
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-09-24 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SA Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
CJ Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Holmes Holding ApS | Company | 66.7% | 66.7% | 2018 |
| Individual | 100.0% | 100.0% | 2023 | |
Afyx Therapeutics A/S | Company | 100.0% | 100.0% | 2023 |
Flovio Labs ApS | Company | 33.3% | 33.3% | 2016 |
| Individual | 20.0% | 20.0% | 2016 | |
| Individual | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Inpare ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Søren Anker Nielsen | Chief Executive Officer | 0 companies |
| Claus Juan Møller-San Pedro | Chief Executive Officer | 0 companies |